化合物Sabizabulin T17228

Product Introduction
Bioactivity


英文名: Sabizabulin

描述: Sabizabulin (ABI-231) 是一种有效且具有口服生物利用度的 α 和 β 微管蛋白抑制剂，可对抗黑色素瘤和前列腺癌细胞系。 Sabizabulin 通过靶向 HPV E6 和 E7 抑制宫颈癌细胞的肿瘤生长和转移表型。 Sabizabulin 显示出抗增殖活性，可用于前列腺癌研究。

体外活性: Sabizabulin (2.5-80 nM) inhibits Panc-1, AsPC-1 and HPAF-II cells growth in a dose and time-dependent manner with IC50s of 25, 35 and 35 nM for 24 hours and 11.8, 15.5, and 25 nM for 48 hours. Sabizabulin (5-20 nM) inhibits pro-Caspase 3 and 9 and activates Caspase-3 and 9 in a dose-dependent manner. Sabizabulin (5-20 nM) induces the expression of Bax and Bad and inhibits the expression of Bcl-2 and Bcl-xl proteins. Sabizabulin (5-20 nM) dose-dependently arrests Panc-1 and AsPC-1 cells in G2/M phase[4].

体内活性: Sabizabulin（50 μg/只小鼠；肿瘤内部注射）强效抑制肿瘤生长，并且未显示出明显的毒性[4]。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (132.49 mM)


关键字: VERU111 | Sabizabulin | ABI 231 | VERU 111 | ABI231

相关产品: EL-102 | Griseofulvin | Tubulin inhibitor 1 | MMAD | Cevipabulin | 10-Deacetyltaxol | Albendazole | DM4 | KIF18A-IN-2 | Flubendazole

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Microtubule-Targeted Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Cancer Clinical Compound Library | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Active Compound Library | Bioactive Compound Library

化合物Sabizabulin T17228信息由TargetMol中国为您提供，如您想了解更多关于化合物Sabizabulin T17228报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途